WHO adapts Ebola vaccination strategy in the Democratic Republic of the Congo to account for insecurity and community feedback
382
2019年5月7日 | 新闻稿 | 日内瓦
7 May 2019 | News release | Geneva
383
世卫组织战略咨询专家组今天发布新建议，以应对与刚果民主共和国现行埃博拉疫情有关的疫苗接种挑战。
WHO’s Strategic Advisory Group of Experts (SAGE) today issued new recommendations to address vaccination challenges in the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC).
384
这些建议包括支持在操作方面的调整，从而加快疫苗接种过程，并根据现有的疗效数据调整剂量。
The recommendations include endorsing operational adjustments that make the vaccination process faster and adjusting the dosage based on available efficacy data.
The SAGE also suggested expanding the population eligible for vaccination with rVSV-ZEBOV-GP (developed by Merck & Co., Inc), introducing an additional experimental vaccine (developed by Johnson & Johnson), and redoubling ongoing efforts to train nurses, doctors and medical students from Ebola-affected communities to work on vaccination teams.
386
疫苗接种可挽救生命，但挑战依存
Vaccinationsaving lives but challenges remain
387
自2018年8月宣布疫情以来，刚果民主共和国已有逾11.1万人接种了疫苗。
More than 111 000 people have been vaccinated in the DRC since the outbreak was declared in August 2018.
However, despite the use of a highly efficacious vaccine , the number of new cases continues to rise, in part due to repeated incidents of violence affecting the ability of response teams to immediately identify and create vaccination rings around all people at risk of contracting Ebola.
389
“我们知道，疫苗在这次疫情中拯救了生命”。
“We know that vaccination is saving lives in this outbreak,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.
390
世卫组织总干事谭德塞博士说。
“We also know that we still face challenges in making sure the contacts of every case receive the vaccine as soon as possible.